OmanDocSign in

Curriculum · Metabolic and Endocrine and Diabetes Mellitus

Insulinoma

What it is

Insulinomas are insulin-secreting pancreatic beta-cell tumors. They are one of the pancreatic endocrine tumors, alongside gastrinoma, glucagonoma and somatostatinoma.

How it presents

Typical clinical features include recurrent attacks of symptomatic hypoglycemia in individuals without diabetes, and weight gain. Palpitation, tremor and blurred vision that are aggravated by playing tennis and relieved by eating carry the same meaning.

Whipple triad holds the features together: a low blood glucose level, signs or symptoms consistent with hypoglycemia, and relief of symptoms when blood glucose increases after treatment.

How it is diagnosed

The biochemical pattern is a glucose below 55 mg/dL with raised insulin, raised C-peptide and raised proinsulin. The full interpretation of laboratory studies for hyperinsulinism runs to six serum levels: in endogenous hyperinsulinism the glucose is low, the insulin elevated, proinsulin and C-peptide normal or high, the β-hydroxybutyrate low, and the serum glucose response to glucagon injection an increase. Against that, exogenous hyperinsulinism has proinsulin and C-peptide low. The raised C-peptide indicates that this insulin is from an endogenous source, since C-peptide is a by-product of endogenous insulin production from the cleavage of proinsulin into insulin and is not present in exogenous sources of insulin. Factitious hypoglycemia secondary to exogenous insulin use will therefore not raise C-peptide levels.

The 72-hour supervised fasting test is the gold standard, and it is the 72-hour observed fasting test that confirms insulinoma biochemically. A CT scan of the abdomen is used after the diagnosis, for localization. The secretin test is for gastrinoma, that is Zollinger-Ellison syndrome, and a serum glucagon level is not diagnostic for hypoglycemia syndromes.